Abstract: A method for comprehensively analyzing and/or evaluating cigarette burning quality index is disclosed. The steps include collecting cigarette burning quality index data, filtering the cigarette burning quality index data, standardizing cigarette data, and measuring cigarette burning quality. The importance of the cigarette burning quality indicators can also be evaluated. The method for comprehensively analyzing and/or evaluating cigarette burning quality indicators can reflect general laws more accurately by maintaining the sample distribution through a singularity detection method, and analyzing correlations of each index with cigarette performance from multiple perspectives, to fuse them into a comprehensive measurement value. The importance ranking and weight of indicators can be obtained more completely and stably.

Abstract: The disclosure belongs to the technical field of liquid crystal materials, and specifically relates to a polymerizable compound, a preparation method therefor, and the use thereof. The polymerizable compound has a structure as shown in general formula I. Compared with the existing polymerizable RM, the polymerizable compound has the advantages of a good solubility, a faster polymerization rate, a more complete extent of polymerization, and less residues, thereby improving the problem of poor display to a great extent.

Abstract: A method for testing burning performance of a dark-colored cigarette using a dark-colored cigarette paper is provided. The dark-colored cigarette paper has a grayscale less than 255. The method includes: simulating, by a robotic arm, a cigarette smoking process and environment; acquiring, by a full-vision camera system, an image of a burn line and ash column region of the dark-colored cigarette; and analyzing a burning performance indicator of the dark-colored cigarette according to coordinate information of the burn line and ash column region. The method is based on a surface reflection characteristic of the dark-colored cigarette paper and a principle of optical reflection to light and highlight an edge of the dark-colored cigarette sample by a light source at a certain angle from a side. In this way, the method forms a chromatic aberration to localize the dark-colored cigarette sample, thereby testing the burning performance of the dark-colored cigarette sample.

Abstract: The present disclosure provides a thermal-stress-pore pressure coupled electromagnetic loading triaxial Hopkinson bar system and test method, the system mainly consists of an electromagnetic pulse generation system, a servo-controlled axial pressure loading system, a servo-controlled confining pressure loading system, a thermal control system, a pore pressure loading system, a bar system, and a data monitoring and acquisition system. Based on the conventional Hopkinson bar, the present disclosure creatively introduces a real-time loading and control system for confining pressure, thermal, and pore pressure, aiming to solve the technical problem that the existing test apparatus cannot be used to study dynamic response of deep rock mass under the coupling effect of thermal-stress-pore pressure and dynamic disturbance during dynamic impact loading.

Abstract: A uniaxial bidirectional synchronous control electromagnetic loaded dynamic shear test system and method, a test apparatus thereof including a support platform, a loading bar system, an electromagnetic pulse generation system, a servo-controlled normal pressure loading system, and a data monitoring and acquisition system. The test apparatus can be used to conduct a dynamic shear test research on a rock-like material under a constant normal pressure close to an actual operating condition, and can also be applied to carry out dynamic shear tests on intact rock-like test specimens in various sizes or jointed rock-like test specimens containing a single structural surface to study dynamic shear mechanical property and shear failure behavior under strain rate of 101?103 s?1, thereby providing an important theoretical and technical support for the design, construction, protection, and safety and stability evaluation of geotechnical engineering, structural engineering.

Abstract: The present invention relates to the technical field of genetics and provides a method for detecting activity change of a transposon in a plant before and after stress treatment. The method includes the following steps: 1) respectively extracting total RNAs of samples before and after stress treatment; 2) respectively constructing cDNA libraries of the samples before and after stress treatment by using the total RNAs; 3) sequencing the cDNA libraries; 4) respectively screening siRNAs from raw sequencing data, and combining the screened siRNAs to obtain a total siRNA, and performing cluster clustering on the total siRNA; 5) extracting repeat in whole genome data by using repeatmasker software to obtain positional information of the plant whole genome transposon; and 6) obtaining activity change in the transposon of the plant before and after treatment by means of change in siRNA cluster expression quantity. The method fills the technical gap in the field of plant transposon activity detections.

Abstract: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.

Abstract: The present invention relates to a chiral spiro-pyridylamidophosphine ligand compound, synthesis method therefor and application thereof. The chiral spiro-pyridylamidophosphine compound is a compound having a structure of Formula (I), a racemate or optical isomer thereof, or a catalytically acceptable salt thereof, and is mainly characterized by having a chiral spiro-dihydro-indene skeleton in its structure. The chiral spiro-pyridylamidophosphine compound may be synthesized with optical active 7-diaryl/alkylphosphino-7?-amino-1,1?-spiro-dihydro-indene or substituted 7-diaryl/alkylphosphino-7?-amino-1,1?-spiro-dihydro-indene having a spiro-skeleton as chiral starting material. The chiral spiro-pyridylamidophosphine compound may be used as a chiral ligand in asymmetric hydrogenation of a carbonyl compound catalyzed by iridium, in which the reaction activity is very high, the amount of the catalyst may be 0.0001 mol %, and the enantioselectivity of the reaction is up to 99.9% ee.

Abstract: The present invention relates to a chiral spiro-pyridylamidophosphine ligand compound, synthesis method therefor and application thereof. The chiral spiro-pyridylamidophosphine compound is a compound having a structure of Formula (I), a racemate or optical isomer thereof, or a catalytically acceptable salt thereof, and is mainly characterized by having a chiral spiro-dihydro-indene skeleton in its structure. The chiral spiro-pyridylamidophosphine compound may be synthesized with optical active 7-diaryl/alkylphosphino-7?-amino-1,1?-spiro-dihydro-indene or substituted 7-diaryl/alkylphosphino-7?-amino-1,1?-spiro-dihydro-indene having a spiro-skeleton as chiral starting material. The chiral spiro-pyridylamidophosphine compound may be used as a chiral ligand in asymmetric hydrogenation of a carbonyl compound catalyzed by iridium, in which the reaction activity is very high, the amount of the catalyst may be 0.0001 mol %, and the enantioselectivity of the reaction is up to 99.9% ee.

Abstract: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.

Abstract: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.

Abstract: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.

Abstract: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.

Abstract: In certain embodiments the invention is directed to an oral solid pharmaceutical dosage form comprising: a first portion of a short acting sedative-hypnotic in an release immediate release component; and a second portion of the sedative-hypnotic in a delayed component, the delayed release component comprising (i) a unitary core comprising the second portion of sedative-hypnotic dispersed in a controlled release matrix and (ii) a delayed release coating surrounding the core.

Abstract: Disclosed is a process for preparing a free base composition of a pharmaceutical compound comprising combining an acid addition salt of a pharmaceutical compound, at least one solvent and a sufficient amount of at least one base to convert the acid addition salt of the pharmaceutical to a free base of the pharmaceutical, to form a free base composition of the pharmaceutical compound.

Abstract: A pharmaceutical sustained release formulation for opioid analgesics which can be administered every 12 hours for control of pain in patients suffering from chronic pain.

Abstract: The invention relates to a rapidly disintegrating oral dosage formulation that contains a water insoluble or slightly water soluble neurological agent and method of preparing the rapidly disintegrating formulation wherein the formulation is designed to dissolve in the buccal cavity of the patient.

Abstract: A naproxen once-a-day matrix tablet is described which is based on a compressed mixture of a controlled release component of said tablet that contains: p1 (i) substantially homogeneous granules of naproxen or a pharmaceutically acceptable salt of naproxen and an organic acid which are prepared by a granulation process which uses a pharmaceutically acceptable film forming material as the binding material;

Abstract: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.

Abstract: A naproxen once-a-day matrix tablet is described which is based on a compressed mixture of a controlled release component of said tablet that contains: